RE:RE:Futureboazklinghorn, "Point being CZO has never ever followed through on anything and until they do..."
That has to be one of the craziest statements I've ever read on Stockhouse. CZO has been one of the most consistent small companies I've ever seen when it comes to following through. Whereas most early-stage businesses eventually fail and do roll-backs, name changes, and change business lines, etc., Gilles had an original vision a decade ago to create a profitable base business with avenanthramide and beta glucan. Now he has a decade long record of double digit growth to go with his original vision. He wanted to use the profits from the base business to turn both avenanthramide and beta glucan into pharma-grade neutraceuticals and he's the first one in human history to achieve both. He received approval from Health Canada to test both under the influencial Dr. Jean-Claude Tardif of the Montreal Heart Institute. While the beta glucan trial didn't reach its desired conclusion even you wanted to give beta glucan a chance in the clinic. You weren't alone. The scientific literature supports a clinical trial for this product too. In the end a liquid version may have succeeded as with the Italian study; but a pill as in CZO's study would have been more convenient. How do you know what works best until you try it. Given CZO's incredibly rich pipeline, developed with follow through, it had to make a choice concerning how to move forward with limited resources. Gilles was originally attracted to CZO because of avenanthramide, which has a $65 billion potential non-steroid anti-inflammatory market dwarfing beta glucan. He's focused resources there. The avenanthramide trial is about to begin! CZO can always go back to beta glucan later and it has learned a bunch from the clinical trial and from the Italian study. Even the beta glucan pill may have product applications given the results. Gilles wants to use CZO's limited resources where there is the best risk-reward. The clear answer for now is avenanthramide. This is why he was originally attracted to CZO!
Gilles and CZO have also been incredibly consistent in the commitment to and follow through with PGX. It was originally developed to help create the beta glucan pill. The pill was successfully developed. PGX has been developed from a concept in a lab to pilot scale and now it is being scaled up to commercial scale. That doesn't happen without follow through. PGX has been investigated for a range of carriers with the best ones(PGX-YBG, PGX-Alginate) now being scaled up. These carriers have been wisely informed by discussions with industry concerning the original prototype PGX-OBG. The prototype has served very useful in the development of PGX. The recent bioavailability results smash PGX-OBG and appear to address the cost issue of industry. CZO now has incredible products to develop - the best it has ever had! PGX-YBG may also be able to serve as a Trojan Horse using macrophages to deliver bioactive greatly expanding the potential. PGX-YBG could turn the immune system into the delivery technology with delivery throughout the body as never before. Given the PGX-YBG bioavailability results over 8 hours what could the immune boosting and energy properties be like? CZO may have industry first first-in-class products for extended release. Can't wait for the results! CZO's PGX-YBG is also being investigated by one of the top universities in the world for fibrosis. The scientist who's led the research is now also with the second largest pharma in the world. He's excited about PGX for fibrosis. Over 40% of deaths world wide are attributable to fibrosis. A 'go', 'no go' decision for clinical trials is expected in the second half of the year.
From the base business, to turning beta glucan and avenanthramide into pharma grade pills, to developing PGX and the ideal carriers the follow though over the last decade has been remarkable and now we are before key catalysts. CZO has even attracted to its Board and as Chairman Canadian pharma icon Ronnie Miller who has been impressed with CZO's follow through! "Mr. Miller commented, “It is my great pleasure to join the Ceapro Board of Directors at this important time as the Company expands its natural ingredient product expertise into additional potential therapeutic indications. To-date the board and management team have built a solid foundation by putting all the pieces in place for long-term growth. As the Company continues to progress, I look forward to actively working alongside the team to maximize the potential and value of Ceapro.”"